Payers

With PCSK9s, payers say, 'Let the market decide'

With PCSK9s, payers say, 'Let the market decide'

By

It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.

A Competitive Market is Good for US Patients

A Competitive Market is Good for US Patients

We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.

Market Access: Looking Back, Looking Ahead

Market Access: Looking Back, Looking Ahead

Securing market access has become significantly more challenging for pharma marketers.

Healthcare industry says it struggles to define value

Healthcare industry says it struggles to define value

By

If value-based care represents the future of healthcare, it needs a better definition, attendees at an HHS forum said.

Drugmakers explore response to pricing debate

Drugmakers explore response to pricing debate

By

Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.

Five things for pharma marketers to know: Friday, November 6, 2015

Five things for pharma marketers to know: Friday, November 6, 2015

By

Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky

FDA issues safety warning for AbbVie's HCV drugs

FDA issues safety warning for AbbVie's HCV drugs

By

One analyst said he expects that the change in label "will meaningfully commercially impair Viekira Pak sales."

Lilly kicks off DTC campaign for Trulicity

Lilly kicks off DTC campaign for Trulicity

By

The drugmaker aims to differentiate its type-2 diabetes drug in the competitive GLP-1 receptor agonist class.

Six things for pharma marketers to know: Thursday, October 8, 2015

Six things for pharma marketers to know: Thursday, October 8, 2015

By

Sanofi's Aubagio reduces brain volume loss; cancer specialists avoid pricey cancer meds; analysis says placebo effect is on the rise

Express Scripts to cover Repatha and Praluent

Express Scripts to cover Repatha and Praluent

By

The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.

Five things for pharma marketers to know: Wednesday, September 30, 2015

Five things for pharma marketers to know: Wednesday, September 30, 2015

By

Teva exec says pharma needs to pay attention to its reputation; academics who serve on boards of healthcare companies face potential conflicts of interest; WHO recommendation will boost number of people taking anti-retrovirals

Docs say that off-label use of PCSK9s is premature

Docs say that off-label use of PCSK9s is premature

By

A panel composed of physicians and medical researchers expressed caution in prescribing PCSK9 inhibitors for off-label uses.

Five things for pharma marketers to know: Wednesday, September 23, 2015

Five things for pharma marketers to know: Wednesday, September 23, 2015

By

Turing CEO backs down on price hike; Amgen's and Allergan's cancer biosimilar shows positive results; study finds text message reminders can change health behavior

Price fixing: PBMs push for lower prices of PCSK9 inhibitors

Price fixing: PBMs push for lower prices of PCSK9 inhibitors

By

Now that the first two PCSK9 inhibitors have been given the thumbs-up by the FDA, the payer community finds itself in a situation comparable to the one it faced upon the arrival of transformative hep.-C drugs: What are they prepared to pay—and which drugs will get the formulary nod? Jaimy Lee assesses the fluid market dynamics

Five things for pharma marketers to know: Monday, September 14, 2015

Five things for pharma marketers to know: Monday, September 14, 2015

By

Entresto's price is too high; Shire may increase its bid for Baxalta; Sanofi's experimental diabetes drug LixiLan met its late-stage trial target

Five things for pharma marketers to know: Wednesday, August 26

Five things for pharma marketers to know: Wednesday, August 26

By

Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review

PCSK9 inhibitors necessitate an update to heart guidelines, CVS Health says

The pharmacy benefit manager said that the introduction of new treatments and clinical evidence on statins demands a rethink to ACC/AHA guidelines

Five things for pharma marketers to know: Monday, August 10

Five things for pharma marketers to know: Monday, August 10

By

CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration

Five things for pharma marketers to know: Friday, August 7

Five things for pharma marketers to know: Friday, August 7

By

CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP

Express Scripts drops Onglyza from 2016 formulary over safety concerns

Express Scripts drops Onglyza from 2016 formulary over safety concerns

By

The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.

Five things for pharma marketers to know: Wednesday, June 3

Five things for pharma marketers to know: Wednesday, June 3

By

Teva is planning to up its stake in Mylan prior to a possible legal challenge; Perrigo acquires GSK OTC portfolio; Express Scripts considers creative ways to drive down drug costs

Five things for pharma marketers to know: Wednesday, May 27

Five things for pharma marketers to know: Wednesday, May 27

By

Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill

FDA panel to review Vertex CF combo therapy on Tuesday

FDA panel to review Vertex CF combo therapy on Tuesday

By

While the FDA is not required to follow the panel's recommendation, the agency's final decision on Orkambi is crucial to Vertex's future.

Five things for pharma marketers to know: Monday, May 4

Five things for pharma marketers to know: Monday, May 4

By

Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways

Study shows women view health differently than industry thinks they do

Study shows women view health differently than industry thinks they do

By

A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.

Five things for pharma marketers to know: Monday, March 30

Five things for pharma marketers to know: Monday, March 30

By

UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals

Top 3 formulary access takeaways for pharma

Top 3 formulary access takeaways for pharma

By

Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks

Five things for pharma marketers to know: Tuesday, February 24

Five things for pharma marketers to know: Tuesday, February 24

By

FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.

Rite Aid buys PBM EnvisionRx for $2B

In a bid to compete with CVS Caremark, pharmacy retailer Rite Aid has purchased pharmacy- benefit manager Envision Pharmaceutical Services.

Email Newsletters